Business

Announcement on Voluntary Disclosure of Initiating Phase I/II Clinical Trial and Completing 1st Subject Enrollment for the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

Announcement on Voluntary Disclosure of Initiating Phase I/II Clinical Trial and Completing 1st Subject Enrollment for the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

articleCansino Biologics, Inc. Class AMay 25, 20264/news/announcement-on-voluntary-disclosure-of-initiating-phase-iii-clinical-trial-and-completing-1st-subject-enrollment-for-the-24-valent-pneumococcal-polysaccharide-conjugate-vaccine-crm197tetanus-toxoid
Announcement on Voluntary Disclosure of Initiating Phase I/II Clinical Trial and Completing 1st Subject Enrollment for the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

About this update from Cansino Biologics, Inc. Class A

Announcement on Voluntary Disclosure of Initiating Phase I/II Clinical Trial and Completing 1st Subject Enrollment for the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Cansino Biologics, Inc. Class A